Background and objective: Obstructive sleep apnoea (OSA) is a prevalent sleep disorder associated with increased cardiovascular morbidity and mortality.
INTRODUCTION
Obstructive sleep apnoea (OSA) is a disorder characterized by recurrent upper airway collapse during sleep.
SUMMARY AT A GLANCE
Commissioned by the Australasian Sleep Association and the Sleep Health Foundation, this statement draws on a panel composed of key sleep medicine stakeholders, including clinicians, researchers, technologists, as well as industry and community groups, to provide consensus of opinion as to the cardiovascular benefits of treating moderate-severe obstructive sleep apnoea. impaired quality of life, increased risk of motor vehicle 2 and workplace accidents. 3 Cross-sectional and prospective cohort studies suggest that patients with moderatesevere OSA are at increased risk for hypertension, cardiovascular disease and cardiovascular events. [4] [5] [6] [7] [8] There is compelling evidence that treating OSA improves sleepiness and has favourable impacts on performance, safety, productivity and mood. [9] [10] [11] [12] However, it is less clear whether the association between moderate-severe OSA and increased cardiovascular risk is causally linked, or if the risk can be ameliorated by treatment. Recent randomized controlled trials (RCT) have shown neutral results when assessing the potential cardiovascular benefit of positive airway pressure (PAP) treatment. 9, 13 The prevalence of OSA amongst the community is high 14, 15 and appears to be growing. 16 Given that OSA can present as minimally symptomatic or asymptomatic, an evidence-informed perspective of the potential longer term cardiovascular health benefits is crucial for determining the focus of goal directed treatment amongst this group.
For most countries, there exists a range of approaches to the diagnosis and treatment of OSA, ranging from limited channel sleep testing to attended in-laboratory polysomnography. Similarly, in Australia, there are a variety of healthcare models that have emerged from which patients receive varied levels of exposure to clinical decision-making inputs from specialist sleep physicians, general practitioners, sleep technologists and industry. Whilst the heterogeneity of this system offers broad choice for clinicians and patients, the system could be further enhanced by collaboration amongst the key stakeholders to ensure that treatment goals remain the same between models and reflect evolving scientific evidence and goal-directed healthcare needs.
While the concept of a collaborative, and consensusbased approach has merit, it requires involvement from all stakeholder groups including clinicians, researchers, industry and community groups. In response, the two peak bodies in Australian sleep medicine (Australasian Sleep Association and Sleep Health Foundation) have formed a consensus committee derived from representatives of the aforementioned stakeholder groups to appraise the evidence supporting a series of statements regarding the cardiovascular benefits from treating moderate-severe OSA, that may add clarity to the evaluation of community based OSA across the array of clinical care models. Given that there is widespread acceptance of the benefits of treatment of OSA on symptoms, the group developed a series of statements focusing on the controversy surrounding the longer term cardiovascular benefits of OSA treatment. 
METHODS

Participants
Methodology
The panel applied a modified RAND/UCLA appropriateness methodology. 17 The panel identified key areas that were then formatted into statements that would allow panellists to respond with a level of agreement to each statement. Each statement was supported by an evidence synthesis from which each panel member drew from before voting. The focus of this consensus process was on key areas of controversy around the longer term cardiovascular benefits derived from OSA treatment. Given that the American Thoracic Society has recently published a comprehensive research statement on the health effects of mild OSA, 18 indicating that there is limited/inconsistent evidence on the impact of treatment of mild OSA on cardiovascular events, the present work focused on patients with moderate-severe OSA (defined by an apnoea-hypopnoea index of >15 events/h).
These statements were: 1. Moderate-severe OSA treatment improves rates of cardiovascular events/death. 2. Moderate-severe OSA treatment improves blood pressure in patients with hypertension. 3. Moderate-severe OSA treatment improves left ventricular function in patients with heart failure. An extensive evidence synthesis of literature pertinent to these statements was conducted by a nonvoting member of panel (S.A.L.). A Medline search of the scientific literature published in English was performed, with evidence synthesis limited to level one (i.e. systematic review/meta-analysis of RCT) and level two evidence (i.e. RCT). Several searches were performed utilizing various combinations of selected terms and MeSH terms including: study type (meta-analysis, systematic review and RCT), disease (OSA, obstructive sleep apn?ea, sleep apn?ea and sleep apn?ea syndromes), treatment (treatment, therapy and therapeutics) and endpoints (mortality, death, cardiovascular diseases, myocardial infarction, heart attack, stroke, blood pressure, hypertension, arrhythmia, ejection fraction and stroke volume).
Each statement was evaluated for agreement. Response options ranged from 1 to 9, with 1-3 indicating disagreement, 4-6 indicating unsure and 7-9 indicating agreement. Panellists also considered whether their voting was based on (i) convincing scientific evidence; (ii) weaker scientific evidence; (iii) expert opinion; or (iv) their own experience. The degree of agreement was assessed by the median score. Consensus was defined by 80% of the panel votes within the same three-point range (i.e. 1-3, 4-6 and 7-9) as the median score.
Panel members cast anonymous votes during two rounds of consensus voting. After the first round, the results were de-identified and circulated to the participants. Prior to the second round, participants met using video conferencing to discuss/debate their interpretation of the literature in light of the first-round voting result.
RESULTS
Of the 299 articles detected, 39 were deemed suitable for full text review. Of these, nine meta-analyses of RCT investigating the effect of OSA treatment on blood pressure were identified [19] [20] [21] [22] [23] [24] [25] [26] [27] and one on the effect of treatment on left ventricular ejection fraction (LVEF). 28 Four RCTs measured the effect of OSA treatment on cardiovascular events or mortality as a primary endpoint. 9, 13, 29, 30 While not indexable at the time of literature synthesis, three recently published metaanalyses investigating the effect of PAP on cardiovascular morbidity and mortality [31] [32] [33] were also included. This evidence was summarized into a review document which was circulated with the original articles to the panel.
The panel's final voting response for each of the three statements is shown in Figure 1 . Consensus was achieved for statements (1) and (2), but not (3) where panel responses demonstrated wider variability.
(1) Moderate-severe OSA treatment improves rates of cardiovascular events/death
As indicated by a median response of 4.5, the panel was unsure whether treating moderate-severe OSA improves cardiovascular morbidly/mortality. Within the panel, there was consensus with 92% (11/12) of members voting with an unsure [4] [5] [6] response. The majority (83%, 10/12) of the panel reported weaker scientific evidence as the basis for their vote.
(2) Moderate-severe OSA treatment improves blood pressure in patients with hypertension
The panel was in agreement that treating moderatesevere OSA improved blood pressure in hypertensive patients, as indicated by a median response of 8. Furthermore, there was complete consensus amongst panel members (12/12) . In accordance with the high volume of meta-analytic reviews on this subject, the panel deemed that this assessment was based on convincing scientific evidence.
(3) Moderate-severe OSA treatment improves left ventricular function in patients with heart failure.
While the median response of 7 indicated agreement with statement (3), variability in responses meant that consensus was not achieved. Specifically, as 75% (9/12) of panel members provided responses indicating agreement, 7-9 consensus was not achieved by only a narrow margin. The majority reported 'weaker scientific evidence' as the basis for their response.
DISCUSSION
This report aims to provide consensus opinion from key stakeholders regarding the potential cardiovascular benefits from treating moderate-severe OSA.
Treat moderate-severe OSA to reduce cardiovascular event/mortality risk?
As reflected in the panel's voting, there is considerable uncertainty in the sleep medicine field regarding whether treatment of moderate-severe OSA can ameliorate cardiovascular event/mortality risk. Panel discussions revealed several reasons for this uncertainty including: (i) disparity in findings between observational and RCT evidence; (ii) concerns regarding the generalizability of RCT findings; and (iii) concerns that PAP adherence in recent RCTs 9 may have been insufficient to establish cardiovascular risk reduction. While observational studies suggested PAP to be beneficial, 7, [34] [35] [36] four recent RCTs assessing cardiovascular event and mortality as a primary outcome 9, 13, 29, 37 have been unable to establish benefits. Furthermore, three recent meta-analyses which draw on mortality and cardiovascular event data from a range of RCTs also provide similar neutral findings. [31] [32] [33] While the evidence from RCTs is strong and consistent, the generalizability of these findings remains contentious.
The majority of RCTs have used a secondary prevention design. 9, 13, 29 It is possible that a treatment benefit may be more readily observed in a primary prevention scenario, where the objective is to intervene when cardiovascular function is better preserved. However, this was not demonstrated in Barbe et al.'s 37 primary prevention trial and any absolute risk reduction in a primary prevention study will be smaller than in a secondary prevention study (due to lower baseline cardiovascular event rate)-thus would require much greater numbers of patients to demonstrate any benefit in a clinical trial.
For ethical reasons the largest RCT, the Sleep Apnea Cardiovascular Endpoints (SAVE) trial (n = 2717), excluded individuals with severe hypoxaemia (oxygen saturation < 80% for >10% of sleep). Furthermore, each of the four RCTs used criteria to exclude patients with excessive daytime sleepiness, such that the majority of recruited individuals reported normal sleepiness levels (Epworth Sleepiness Scale [ESS] < 10) despite suffering moderate-severe OSA. Importantly, meta-analytic evidence suggests that PAP is less effective in reducing blood pressure in non-sleepy OSA patients. 26 Therefore, while RCT evidence suggests PAP may be ineffective at reducing cardiovascular risk, this may not be generalizable to patients who suffer excessive daytime sleepiness. One potential reason why non-sleepy patients do not obtain cardiovascular benefit from PAP therapy is that such individuals tend to demonstrate poorer adherence. 26 PAP usage has averaged between~5 and 6 h for the majority of recent RCTs 13, 29, 37 ; however, measures of variance suggest considerable proportions of participants achieved poorer adherence. Notably in the SAVE trial, average PAP usage was particularly low at 3.3 AE 2.3 h/ night. Three RCTs 13, 29, 37 provide evidence suggesting that greater reductions in cardiovascular risk occur in individuals who achieved higher nightly PAP usage (>3-4 h/night). However, these forms of adherencebased post hoc analysis are confounded by 'healthy adherer effects'. That is, patients who adhere well to PAP are also more adherent to other medications, 38 and may also partake in a range of other unmeasured healthy lifestyle choices that could also ameliorate longterm cardiovascular risk. An expanded review of this recent literature can be found in a white paper provided by the International Collaboration of Sleep Apnoea Cardiovascular Trialists (INCOSANT) initiative. 39 In summary, if treatment of OSA does improve cardiovascular risk, it is unlikely to be a robust effect and may only exist under specific circumstances. While it is established that treatment should be offered to all symptomatic patients, long-term cardiovascular benefit cannot be expected.
Treat moderate-severe OSA to reduce blood pressure in subjects with hypertension?
Complete consensus agreement was achieved for the position that treatment of moderate-severe OSA can improve blood pressure. This is supported by level one evidence on this topic; however, there are caveats concerning which patients will benefit most. Specifically, patients experience greater treatment related improvements in blood pressure if they have severe OSA, 20, 22, 24, 25 suffer from hypertension at baseline or demonstrate resistant hypertension 21, 23, 27 or have subjective sleepiness complaints (ESS > 11).
24,25 PAPrelated improvements to blood pressure while significant are relatively small in effect size (~systolic blood pressure (SBP) = −1.4 to 2.6, diastolic blood pressure (DBP) = −1.5 to 2.0 mm Hg; in hypertensive subgroup SBP = −2.3 to 7.1,~DBP~2.0-4.3 mm Hg 23, 27 ) and direct comparisons between PAP and blood pressure medication demonstrate that the effect of PAP is approximately four times smaller than Valsartan. 40 However, there is evidence of an additive effect on blood pressure reduction, 27, 40 suggesting a role from combining PAP and antihypertensive medication in patients who demonstrate resistant hypertension.
Evidence supports a role for PAP therapy as an adjunctive treatment for controlling hypertension which may be more useful when OSA is severe, associated with sleepiness and blood pressure remains elevated despite treatment with antihypertensive medication (resistant hypertension).
Treat moderate-severe OSA to improve left ventricular function in heart failure?
While there was general agreement that treatment of OSA can improve left ventricular function, consensus was not obtained. Meta-analytic evidence suggests that treatment of OSA with PAP can improve LVEF by +3.6%. 28 This effect is smaller (+1.1%) and not statistically significant in those without substantially impaired LVEF at baseline. In OSA patients with co-morbid heart failure, PAP improves LVEF to a greater extent (+5.2%), and to a similar magnitude to beta-blocker medications (+4.6 to 8.6% 41 ). Despite this, consensus was not achieved as some panel members cited lack of evidence for the clinical significance of these effect sizes. Furthermore, there were concerns that high-level evidence examining the impact PAP therapy has on LVEF is relatively sparse; amounting to a single meta-analysis of 10 RCTs which are of generally small sample size (n: 17-45) and predominantly composed of male participants (all > 87% males). Importantly, only six of these trials recruited individuals with heart failure. Subjective sleepiness does not appear to be related improvement in LVEF; however, ESS was only reported in five of the trials.
The present work has limitations that require consideration. Despite the use of a rigorous RAND/ UCLA appropriateness methodology, this consensus statement still reflects a voting-based subjective assessment of the current available evidence. Moreover, unlike other consensus positions which are typically composed solely of content experts, the current panel employed a multi-disciplinary panel that included key industry, technology and community stakeholder groups in addition to academic and clinical content experts. This approach was specifically chosen as it was believed that this would have the greatest likelihood of influencing clinical practice across the various disparate models of care currently in place across Australia. It should be noted however that due to constraints on the size of the consensus panel, two of the community groups (Australasian Sleep Technologists Association and Sleep Disorders Australia) only had one representative. While a strength of this review is that evidence synthesis was limited to high-level (levels 1 and 2) evidence, this further exposed the currently limited scope of evidence in this area of research. There is an urgent need for more long-term randomized trials assessing OSA treatment on cardiovascular end points such as cardiovascular event rates, LVEF and arrhythmia. Where ethically permissible, further systematic investigation is also needed into patient factors which likely influence treatment responses (such as baseline cardiovascular status, sleepiness symptoms and PAP dose). Finally, as the majority of investigations have focused on PAP therapy, there is a need for further randomized trials investigating the long-term cardiovascular benefits of non-PAP therapies, such as oral appliance therapies and upper airway surgical interventions.
On the basis of this evidence review, the panel has achieved consensus on two of the three key statements that reflect controversy as to whether they serve as treatment goals in the management of OSA. 
